Review
Biochemistry & Molecular Biology
Skye Montoya, Deborah Soong, Nina Nguyen, Maurizio Affer, Sailasya P. Munamarty, Justin Taylor
Summary: Development of targeted therapies has provided nonchemotherapeutic options for patients, with small molecule kinase inhibitors being a key focus. However, resistance to these therapies may develop, necessitating multiple lines of treatment. Combinations of therapies targeting complimentary pathways may be more effective in overcoming drug resistance.
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Oncology
Prachi Mishra, Dipranjan Laha, Robert Grant, Naris Nilubol
Summary: This article reviews current treatment practices for thyroid cancer and emphasizes on novel targeted molecular therapy. With rapidly expanding knowledge of the molecular biology and increased availability of genetic testing, exciting paradigm shifts in treatment strategies have been observed. Targeted therapies and personalized treatments have become a trend with the development of new treatment strategies, accelerating the advancement of treatments for thyroid cancer.
Review
Pharmacology & Pharmacy
Isha Bansal, Amit Kumar Pandey, Munindra Ruwali
Summary: Breast cancer is the most common malignancy in women worldwide and despite advancements in cancer detection and treatment, it remains the leading cause of women's malignancy related deaths. Understanding the biology of breast cancer and developing new diagnostic and therapeutic strategies have gained renewed focus in recent studies.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Chemistry, Medicinal
Adileh Ayati, Setareh Moghimi, Mahsa Toolabi, Alireza Foroumadi
Summary: Despite advancements in cancer treatment, EGFR inhibitors have shown significant improvement in targeted therapy. However, the emergence of epigenetic mutation and resistance issues have limited their effectiveness, leading to the need for further research in this field. Recent studies have focused on genetic alterations in the EGFR tyrosine kinase domain, resulting in the development of more selective and effective inhibitors.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Chemistry, Multidisciplinary
Jia Zheng, Wei Zhang, Linfeng Li, Yi He, Yue Wei, Yongjun Dang, Shenyou Nie, Zufeng Guo
Summary: Targeted therapy is a groundbreaking innovation in cancer treatment, with FGFRs being recognized as promising therapeutic targets. Several generations of FGFR kinase inhibitors have been developed over the past two decades.
FRONTIERS IN CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang, Shengyong Yang
Summary: Targeted therapeutic drugs have become mainstream cancer treatments due to their advantages in efficacy and safety, but still face challenges such as low response rate and drug resistance. A comprehensive review was conducted on small-molecule targeted anti-cancer drugs to promote their development, discussing current challenges and providing insights and perspectives for future research and development.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Review
Pharmacology & Pharmacy
Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Calina, Massimo Libra, Luca Falzone
Summary: Lung cancer is the second most diagnosed tumor with the highest mortality rate. Recent progress in the treatment of lung cancer includes targeted therapies and immunotherapy, which have been approved in clinical practice. This review discusses the current and ongoing clinical studies on targeted therapies and immune-checkpoint inhibitors for lung cancer, as well as the advantages and limitations of these new therapeutic approaches. Furthermore, the importance of human microbiota as biomarkers and therapeutic targets for lung cancer is analyzed. The future research milestones in personalized treatment for lung cancer are expected to consider the genetic landscape, immune background, and individual variables such as patient-specific gut microbial composition.
Article
Immunology
Richard M. Powell, Marlies J. W. Peeters, Anne Rahbech, Pia Aehnlich, Tina Seremet, Per Thor Straten
Summary: This study investigates the impact of new generation and potent MERTK/FLT3 receptor tyrosine kinase inhibitors on human primary CD8(+) T cell function, revealing that the use of a dual MERTK/FLT3 inhibitor restricts CD8(+) T cell proliferation while largely leaving cytokine production and activation unaffected. Additionally, the study shows that activated CD8(+) T cells express FLT3 early on post-activation, and inhibition of FLT3 affects cell cycle kinetics. These results highlight the need for caution when using potent RTKIs in the context of antitumor immune responses.
Review
Biochemistry & Molecular Biology
Marco de Scordilli, Anna Michelotti, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz
Summary: The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSCLC) is rapidly evolving. Molecular analysis and PD-L1 evaluation have become routine assessments. New treatment options have been approved, including osimertinib for EGFRm patients and ICIs in both adjuvant and neoadjuvant settings. However, mature data on overall survival benefits are not yet available.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Lucia Gandullo-Sanchez, Alberto Ocana, Atanasio Pandiella
Summary: HER3 protein is closely associated with the development of various tumors, and targeting HER3 has therapeutic relevance in promoting cell proliferation. Different types of agents targeting HER3 have been developed, including antibodies, aptamers, and vaccines. This article reviews the preclinical and clinical development of drugs targeting HER3.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Ningning Yan, Sanxing Guo, Huixian Zhang, Ziheng Zhang, Shujing Shen, Xingya Li
Summary: This review summarizes the characteristics and challenges of BRAF mutations in NSCLC, as well as the treatment strategies and resistance mechanisms of BRAF-targeted therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Aimee Rendell, Isobel Thomas-Bland, Lee McCuish, Christopher Taylor, Mudra Binju, Yu Yu
Summary: Ovarian cancer is a deadly gynecological malignancy. Targeting receptor tyrosine kinases has shown potential for treating ovarian cancer, but monotherapeutic agents have not been effective. Combination therapy with tyrosine kinase inhibitors and monoclonal antibodies appears more promising, especially in platinum-sensitive tumors. Immunotherapeutic vaccines have also shown some efficacy but require further development.
Article
Biochemistry & Molecular Biology
Nidhi Saini, Ajmer Singh Grewal, Viney Lather, Suresh Kumar Gahlawat
Summary: Phytochemicals contribute to protection and interaction processes by acting as antioxidants, anti-mutagens, anticarcinogens, and antimicrobial agents. In this study, sanguinarine was found to be the most potent inhibitor of epidermal growth factor receptor (EGFR) compared to erlotinib. Other alkaloids also showed potent inhibition against EGFR, but their stability with EGFR varied. Out of the 31 alkaloids subjected to ADMET prediction, 29 alkaloids followed Lipinski's rule of five and were predicted to have high bioavailability, low toxicity, and ease of synthesis.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Review
Biology
Terry W. Moody, Irene Ramos-Alvarez, Robert T. Jensen
Summary: Cancer growth is regulated by receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCRs). Different mutations in EGFR and NTSR1 can lead to abnormal cancer proliferation. The use of tyrosine kinase inhibitors and SR48692 as antagonists can impair the transactivation process and inhibit cancer growth.
Article
Immunology
Parisa Sarvarian, Parisa Samadi, Elham Gholipour, Karim Shams Asenjan, Mohammad Hojjat-Farsangi, Roza Motavalli, Farhad Motavalli Khiavi, Mehdi Yousefi
Summary: Nanotechnology enables the delivery of small molecular drugs packaged in nanosized vesicles to target tissues. Plant-Derived Nanoparticles (PDNPs), with natural origin and unique properties, can be modified based on the specificity of their functions in target tissues, making them potential drug delivery systems for diseased tissues.
IMMUNOLOGICAL INVESTIGATIONS
(2022)
Article
Immunology
Amin Kamrani, Mohammad Sadegh Soltani-Zangbar, Sadaf Shiri, Yousef Yousefzadeh, Ramin Pourakbari, Leili Aghebati-Maleki, Amir Mehdizadeh, Shahla Danaii, Farhad Jadidi-Niaragh, Bahman Yousefi, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Roza Motavalli, Mohammadali Zolfaghari, Mostafa Haji-Fatahaliha, Ata Mahmoodpoor, Javad Ahmadian Heris, Asma Emdadi, Mehdi Yousefi
Summary: The study found that the frequency of TIGIT(+) and CD155(+) CD4(+) T cells was significantly decreased in patients with preeclampsia (PE), and there was an imbalance in the levels of related inflammatory and inhibitory cytokines. Blocking TIGIT and CD155 may lead to an increase in inflammatory cytokines and a decrease in anti-inflammatory cytokines, indicating an inflammatory status polarization in PE patients.
IMMUNOLOGICAL INVESTIGATIONS
(2022)
Article
Medicine, Research & Experimental
Fariba Karoon Kiani, Sepideh Izadi, Ehsan Ansari Dezfouli, Farbod Ebrahimi, Mohammad Mohammadi, Hengameh Chalajour, Mirmohammad Mortazavi Bulus, Maryam Nasr Esfahani, Vahid Karpisheh, Armin Mahmoud Salehi Khesht, Kazem Abbaszadeh-Goudarzi, Ali Soleimani, Jamshid Gholizadeh Navashenaq, Majid Ahmadi, Hadi Hassannia, Mohammad Hojjat-Farsangi, Sima Shahmohammadi Farid, Vida Hashemi, Farhad Jadidi-Niaragh
Summary: This study successfully inhibited the expression of PD-1 and A2aR on tumor-associated T cells using nanoparticles loaded with anti-PD-1/A2aR siRNAs, enhancing T cell functions and suppressing tumor growth in mouse models, leading to increased anti-tumor immune responses and survival time.
Article
Oncology
Ramin Pourakbari, Mehdi Yousefi, Balal Khalilzadeh, Mahsa Haddad Irani-nezhad, Alireza Khataee, Leili Aghebati-Maleki, Alireza Soleimanian, Amin Kamrani, Forough Chakari-Khiavi, Rozita Abolhasan, Morteza Motallebnezhad, Farhad Jadidi-Niaragh, Bahman Yousefi, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Mohammad-Reza Rashidi
Summary: In this study, a novel biosensing method based on WS2 QDs-Au was developed for rapid and selective detection of c-Met protein. The method was applied for the electrochemical detection of c-Met protein as a colon cancer biomarker and showed good detection performance in serum samples.
CANCER NANOTECHNOLOGY
(2022)
Review
Oncology
Atefeh Khodakarami, Sara Adibfar, Vahid Karpisheh, Shiva Abolhasani, Pooya Jalali, Hamed Mohammadi, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat-Farsangi, Farhad Jadidi-Niaragh
Summary: NF-E2-related factor 2 (Nrf2) transcription factor has contradictory roles in cancer, it can act as a tumor suppressor or a proto-oncogene. Nrf2 regulates multiple cellular processes and plays a crucial role in cell survival. However, Nrf2 also protects cancer cells from apoptosis and promotes tumor growth and metastasis.
CANCER CELL INTERNATIONAL
(2022)
Article
Immunology
Sahar Madadi, Sina Mohammadinejad, Amin Alizadegan, Mohammad Hojjat-Farsangi, Sanam Dolati, Hossein Samadi Kafil, Farhad Jadidi-Niaragh, Mohammad Sadegh Soltani-Zangbar, Roza Motavalli, Jalal Etemadi, Shadi Eghbal-Fard, Leili Aghebati-Maleki, Shahla Danaii, Simin Taghavi, Mehdi Yousefi
Summary: This research evaluates the expression levels of immune checkpoint factors in normal pregnant women and PE patients and finds that the expression of these factors is significantly decreased in PE patients, which may lead to abnormal immune response.
Article
Biochemistry & Molecular Biology
Shiva Abolhasani, Seyyed Sina Hejazian, Vahid Karpisheh, Atefeh Khodakarami, Hamed Mohammadi, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat-Farsangi, Farhad Jadidi-Niaragh
Summary: The discovery of new genes/pathways in cancer research provides novel therapeutic options, and understanding the roles and therapeutic potential of SF3B1 and NOTCH1 in leukemia pathogenesis is crucial for advancing leukemia treatment.
Article
Chemistry, Multidisciplinary
Asal Barshidi, Vahid Karpisheh, Fatemeh Karimian Noukabadi, Fariba Karoon Kiani, Mohammad Mohammadi, Negin Afsharimanesh, Farbod Ebrahimi, Seyed Hossein Kiaie, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat-Farsangi, Naime Majidi Zolbanin, Ata Mahmoodpoor, Hadi Hassannia, Sanam Nami, Pooya Jalali, Reza Jafari, Farhad Jadidi-Niaragh
Summary: This study suggests that nanoparticles loaded with siRNA can effectively inhibit the expression of immune checkpoints, leading to increased efficiency of T cells in response to vaccines. Furthermore, the combination of these nanoparticles and DC vaccines has shown promising results in inhibiting tumor growth and improving survival in mice. These findings highlight the potential of combination therapy targeting immune checkpoints for cancer treatment.
PHARMACEUTICAL RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Abbas Ali Hosseinpour Feizi, Sajjad Vakili-Samiani, Vahid Karpisheh, Ali Masjedi, Sepideh Izadi, Sara Adibfar, Afshin Nikkhoo, Mohammad Hojjat-Farsangi, Fatemeh Atyabi, Omid Joodi Khanghah, Ali Akbar Movassaghpour, Saeed Solali, Mehdi Yousefi, Farhad Jadidi-Niaragh
Summary: This study used TAT-PEG-CCMD nanoparticles to deliver anti-WEE1 siRNA and Dox to ALL cells, which effectively inhibited WEE1 kinase overexpression and enhanced the apoptotic effects of Dox. These findings suggest that this combination therapy could be a promising approach for treating ALL.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Medicine, Research & Experimental
Sara Adibfar, Ali Masjedi, Atefeh Nazer, Bentolhoda Rashidi, Vahid Karpisheh, Sepideh Izadi, Hadi Hassannia, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mohammad Hojjat-Farsangi, Hanieh Tarokhian, Farhad Jadidi-Niaragh
Summary: The study found that inhibiting CD73/EZH2 factors using SPION-TMC-FA NPs may be a promising strategy for treating breast cancer, reducing cancer development and enhancing anti-tumor immune responses.
Article
Biochemistry & Molecular Biology
Yousef Yousefzadeh, Mohammad Sadegh Soltani-Zangbar, Ladan Kalafi, Ali Tarbiat, Sima Shahmohammadi Farid, Leili Aghebati-Maleki, Forough Parhizkar, Shahla Danaii, Simin Taghavi, Farhad Jadidi-Niaragh, Hossein Samadi Kafil, Ata Mahmoodpoor, Javad Ahmadian Heris, Mohammad Hojjat-Farsangi, Mehdi Yousefi
Summary: This study evaluated the expression of adenosine and hypoxia-related signaling molecules in preeclampsia patients and found aberrant expression of these molecules associated with hypertension and inflammation.
MOLECULAR BIOLOGY REPORTS
(2022)
Article
Obstetrics & Gynecology
Ramin Pourakbari, Forough Parhizkar, Mohammad Sadegh Soltani-Zangbar, Parisa Samadi, Majid Zamani, Leili Aghebati-Maleki, Roza Motavalli, Ata Mahmoodpoor, Farhad Jadidi-Niaragh, Bahman Yousefi, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Shahla Danaii, Mehdi Yousefi
Summary: This study identifies the impact of preeclampsia (PE) exosomes on the activity of Th17 and Treg cells and their related gene expression and cytokine profiles in healthy pregnant women. PE patients exhibited decreased Treg cell number and increased Th17 cells, while intervention with PE exosomes led to significant changes in gene expression and cytokine levels. These findings suggest a possible role of PE exosomes in the pathogenesis of PE.
REPRODUCTIVE SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
Summary: This article reviews the role of CTLA-4 in different subtypes of Hematological Malignancies (HMs), including its expression pattern, its effect on prognosis, and polymorphisms. The article also discusses the effects of targeting CTLA-4 in vitro, in vivo, and in clinical trials. According to recent literature, CTLA-4 is overexpressed in different HMs and is associated with poor survival, except in Chronic Lymphocytic Leukemia (CLL) where it is associated with better prognosis. Targeting CTLA-4 is helpful in certain HMs but not recommended in others. Certain CTLA-4 gene polymorphisms also play a significant role in the course of HMs. Future studies will further our understanding of the role of CTLA-4 in HMs.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2023)
Review
Cell Biology
Mohammad Sadeghi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Afshin Namdar, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
Summary: Heme oxygenase-1 (HO-1) is overexpressed in hematological malignancies and associated with disease severity. It induces tumor progression and prevents apoptosis through various pathways, making it a potential therapeutic target. However, the exact role of HO-1 in Chronic Lymphocytic Leukemia (CLL) remains unclear.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Pharmacology & Pharmacy
Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Osterborg, Hakan Mellstedt, Mohammad Hojjat-Farsangi
Summary: This study evaluated the expression of ROR1 in NSCLC patients and the cytotoxic effects of a small molecule ROR1 inhibitor in NSCLC cell lines. ROR1 was overexpressed in non-squamous and squamous carcinomas, as well as neuroendocrine tumors. The ROR1 inhibitor dephosphorylated ROR1 and induced apoptosis, and also inhibited the proliferation and migration of NSCLC cells. The combination of the ROR1 inhibitor and EGFR inhibitor showed a synergistic apoptotic effect.
